Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Angling Times review and compare the best short feeder fishing rods on the market currently. Rods ideally suited to ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

March 29, 2025: We’re starting to add the new Fisch rods from the Second Sea update. What is the best Fisch rod? It’s a complicated question. You can’t just jump from the beginner rod to the ...

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, March 17, 2025. REUTERS/Staff/File Photo World stock markets and oil prices tumbled and investors ...

10% chance to get the King’s Blessing mutation 1,555,555C$ The S Tier consists of some of the most overpowered rods in Fisch. Among these, the newly added Ethereal Prism Rod is currently one of the ...